Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells.
Somatostatin analogues (SSA) represent the standard of care for symptom control in patients with functional gastro-entero-pancreatic neuroendocrine tumors (GEP-NET). In addition, SSA exert significant anti-proliferative effects in mid-gut and pancreatic NET (PanNET). In parallel, molecularly targete...
Main Authors: | Sebastian Krug, Jan-Philipp Mordhorst, Fabian Moser, Katharina Theuerkorn, Claudia Ruffert, Maren Egidi, Anja Rinke, Thomas M Gress, Patrick Michl |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0218953 |
Similar Items
-
Correction: Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells.
by: Sebastian Krug, et al.
Published: (2020-01-01) -
Medical Treatment of Gastroenteropancreatic Neuroendocrine Tumors
by: Thomas Gress, et al.
Published: (2012-02-01) -
Brain metastases in patients with neuroendocrine neoplasms: risk factors and outcome
by: Sebastian Krug, et al.
Published: (2019-04-01) -
Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
by: Anna Kathrin Stueven, et al.
Published: (2019-06-01) -
Somatostatin analogues in the therapy of neuroendocrine tumors: Indications, contraindications, side-effects
by: Beata Polowczyk, et al.
Published: (2020-07-01)